Regulation profile of phosphatidylcholines (PCs) and lysophosphatidylcholines (LPCs) components towards UDP-glucuronosyltransferases (UGTs) isoforms

Xenobiotica

Volumn 45, Issue 3, 2015, Pages 197-206

  Gao, Xin ^a   Qu, Hengyan ^a   Ai, Chun Zhi ^c   Cao, Yun Feng ^d   Huang, Ting ^d   Chen, Jian Xing ^d   Zeng, Jia ^d   Sun, Xiao Yu ^c   Hong, Mo ^c   Gonzalez, Frank J ^e   Liu, Zeyuan ^a   Fang, Zhong Ze ^b  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^d SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Allosteric activation; Lysophosphatidylcholines; Phosphatidylcholine; UDP glucuronosyltransferases

Indexed keywords

GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A8; HYMECROMONE; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; TRIFLUOPERAZINE; GLUCURONIDE; ISOPROTEIN; RECOMBINANT PROTEIN;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; GLUCURONIDATION; IN VITRO STUDY; INCUBATION TIME; INHIBITION KINETICS; PHENOTYPE; REGULATORY MECHANISM; BIOCATALYSIS; CHEMISTRY; ENZYME ACTIVE SITE; HUMAN; KINETICS; METABOLISM; MOLECULAR DOCKING;

BIOCATALYSIS; CATALYTIC DOMAIN; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; KINETICS; LYSOPHOSPHATIDYLCHOLINES; MOLECULAR DOCKING SIMULATION; PHOSPHATIDYLCHOLINES; PROTEIN ISOFORMS; RECOMBINANT PROTEINS;

EID: 84924039137     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2014.966174     Document Type: Article

References (21)

1. Bock KW, Kohle C. (2005). UDP-glucuronosyltransferase 1A6: structural, functional, and regulatory aspects. Methods Enzymol 400: 57-75.
2. Diatlovitskaia EV, Lemenovskaia AF, Archakov AI, et al. (1977). Alteration of the lipid composition of rat liver microsomes on reconstitution of the cytochrom P-450 system. Inactivation of the enzyme by lysolecithin. Biokhimiia 42:139-43.
3. Diatlovitskaia EV, Petkova DKH, Bergel'son LD. (1982). Lipid dependence of the activity of cytochrome P-450 from microsomes of rat liver by the phosphatidylcholine transfer protein from bovine liver. Biokhimiia 47:1366-9.
4. Dragacci S, Thomassin J, Magdalou J, et al. (1987). Properties of human hepatic UDP-glucuronosyltransferases. Relationship to other inducible enzymes in patients with cholestasis. Eur J Clin Pharmacol 32: 485-91.
5. Dura P, Salomon J, Te Morsche RH, et al. (2012). High enzyme activity UGT1A1 or low activity UGT1A8 and UGT2B4 genotypes increase esophageal cancer risk. Int J Oncol 40:1789-96.
6. Fang ZZ, Cao YF, Hu CM, et al. (2013a). Structure-inhibition relationship of ginsenosides towards UDP-glucuronosyltransferases (UGTs). Toxicol Appl Pharmacol 267:149-54.
7. Fang ZZ, He RR, Cao YF, et al. (2013b). A model of in vitro UDP-glucuronosyltransferase inhibition by bile acids predicts possible metabolic disorders. J Lipid Res 54:3334-44.
8. Fang ZZ, Krausz KW, Tanaka N, et al. (2013c). Metabolomics reveals trichloroacetate as a major contributor to trichloroethylene-induced metabolic alterations in mouse urine and serum. Arch Toxicol 87: 1975-87.
9. Han MS, Lim YM, Quan W, et al. (2011). Lysophosphatidylcholine as an effector of fatty acid-induced insulin resistance. J Lipid Res 52: 1234-46.
10. Ishii Y, An K, Nishimura Y, Yamada H. (2012). ATP serves as an endogenous inhibitor of UDP-glucuronosyltransferase (UGT): a new insight into the latency of UGT. Drug Metab Dispos 40:2081-9.
11. Kokawa Y, Kishi N, Jinno H, et al. (2013). Effect of UDPglucuronosyltransferase 1A8 polymorphism on raloxifene glucuronidation. Eur J Pharm Sci 49:199-205.
12. Lagace TA, Ridgway ND. (2013). The role of phospholipids in the biological activity and structure of the endoplasmic reticulum. Biochim Biophys Acta 1833:2499-510.
13. Mackenzie PI. (2000). Identification of uridine diphosphate glucuronosyl transferases involved in the metabolism and clearance of mycophenolic acid. Ther Drug Monit 22:10-3.
14. Matsumoto T, Kobayashi T, Kamata K. (2007). Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr Med Chem 14: 3209-20.
15. Meza-Junco J, Chu QS, Christensen O, et al. (2009). UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. Cancer Chemother Pharmacol 65:1-4.
16. Tsoutsikos P, Miners JO, Stapleton A, et al. (2004). Evidence that unsaturated fatty acids are potent inhibitors of renal UDPglucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol 67:191-9.
17. Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO. (2006). Selectivity of substrate (trifl uoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfi npyrazone) "probes" for human UDP-glucuronosyltransferases. Drug Metab Dispos 34:449-56.
18. Wenk MR. (2005). The emerging field of lipidomics. Nat Rev Drug Discov 4:594-610.
19. Xiao Y, Guengerich FP. (2012). Metabolomic analysis and identification of a role for the orphan human cytochrome P450 2W1 in selective oxidation of lysophospholipids. J Lipid Res 53:1610-7.
20. Zakim D, Eibl H. (1992). The influence of charge and the distribution of charge in the polar region of phospholipids on the activity of UDP-glucuronosyltransferase. J Biol Chem 267:13166-70.
21. Zucker SD, Qin X, Rouster SD, et al. (2001). Mechanism of indinavirinduced hyperbilirubinemia. Proc Natl Acad Sci USA 98:12671-6.